Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Flotetuzumab

😃Good
Catalog No. T77012Cas No. 1664355-28-5

Flotetuzumab (MGD006; S80880), an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule, reactivates T cells through concurrent engagement with CD123 on target cells and CD3 on effector T cells, facilitating T-cell-mediated cytotoxicity in target cells. Demonstrating an inhibitory effect in a mouse model of patient-derived xenograft (PDX) for acute myeloid leukemia (AML) [1] [2], Flotetuzumab offers potential therapeutic prospects for AML treatment.

Flotetuzumab

Flotetuzumab

😃Good
Catalog No. T77012Cas No. 1664355-28-5
Flotetuzumab (MGD006; S80880), an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule, reactivates T cells through concurrent engagement with CD123 on target cells and CD3 on effector T cells, facilitating T-cell-mediated cytotoxicity in target cells. Demonstrating an inhibitory effect in a mouse model of patient-derived xenograft (PDX) for acute myeloid leukemia (AML) [1] [2], Flotetuzumab offers potential therapeutic prospects for AML treatment.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$6222-4 weeks2-4 weeks
5 mg$1,5802-4 weeks2-4 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Flotetuzumab (MGD006; S80880), an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule, reactivates T cells through concurrent engagement with CD123 on target cells and CD3 on effector T cells, facilitating T-cell-mediated cytotoxicity in target cells. Demonstrating an inhibitory effect in a mouse model of patient-derived xenograft (PDX) for acute myeloid leukemia (AML) [1] [2], Flotetuzumab offers potential therapeutic prospects for AML treatment.
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
Endotoxin< 1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetCD123/CD3
Chemical Properties
Cas No.1664355-28-5
Antibody Information
IsotypeScFv
Storage & Solubility Information
Storage-20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Flotetuzumab | purchase Flotetuzumab | Flotetuzumab cost | order Flotetuzumab